Chemomab Therapeutics Ltd
NASDAQ:CMMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chemomab Therapeutics Ltd
Other Long-Term Assets
Chemomab Therapeutics Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Other Long-Term Assets
$211k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Long-Term Assets
$1.4m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
30%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Long-Term Assets
$582.9m
|
CAGR 3-Years
1 024%
|
CAGR 5-Years
466%
|
CAGR 10-Years
168%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Long-Term Assets
$5.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Long-Term Assets
$96k
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Other Long-Term Assets
$2.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
30%
|
CAGR 10-Years
14%
|
|
Chemomab Therapeutics Ltd
Glance View
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
See Also
What is Chemomab Therapeutics Ltd's Other Long-Term Assets?
Other Long-Term Assets
211k
USD
Based on the financial report for Dec 31, 2025, Chemomab Therapeutics Ltd's Other Long-Term Assets amounts to 211k USD.
What is Chemomab Therapeutics Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
29%
Over the last year, the Other Long-Term Assets growth was -45%. The average annual Other Long-Term Assets growth rates for Chemomab Therapeutics Ltd have been -34% over the past three years , 29% over the past five years .
